Lobomycosis

Back

Background

Lobomycosis (lacaziosis) is a self-limited, chronic fungal infection of the skin endemic in rural regions in South America and Central America. Natives of the Brazilian rain forest call this disease miraip or piraip, meaning "that which burns."

Jorge Lobo first described this infection in the medical literature[1] as keloidal blastomycosis in a patient from the Amazon Valley of Brazil. Since the original report, lobomycosis has been reported in many South American countries, in North American travelers to endemic regions, closely related disease in two species of Atlantic dolphins, and in one marine park dolphin trainer.[2]

The condition was called Lobo disease in 1938, in 1958 the name lobomycosis was applied, and in 2005 the name lacaziosis was suggested.[3, 4, 5]

Three species names have been recommended: Loboa loboi[6] ; Paracoccidioides loboi[7] because of its antigenic relationship to Paracoccidioides brasiliensis; and Lacazia loboi[8] in deference to Lacaz, who contributed much to the knowledge of the disease. Other names that have been used are Glenosporella loboi and Blastomyces loboi. Based on recent molecular studies, the name Lacazia loboi is the current recommended name.[5] As is common in medical mycology, the name of the disease is taken from the genus of the etiologic agent, and therefore, lacaziosis has been proposed for the disease name rather than lobomycosis.[5]

Phylogenetic and genomic analyses indicate that it is a sister taxon of the human dimorphic fungal pathogen P brasiliensis and that both species belong to the order Onygenales.[5, 9, 10, 11]

Pathophysiology

The organism responsible for lobomycosis has yet to be cultured in vitro. The infection has been transmitted to an armadillo,[12] to the footpads and cheek pouches of golden hamsters,[13, 14] and to tortoises.[15] Live organisms have been maintained for 18 months in the footpads of BALB/c mice.[16, 17, 18] However, most of our knowledge of the etiologic agent of lobomycosis is derived from histopathologic, electron microscopic, and molecular studies.[5]

The fungus is abundant in lobomycotic skin lesions. It is a spherical intracellular yeast 6-12 μm diameter.[19] The fungus is remarkably homogeneous, with an average diameter of 9 μm. Although debate exists as to whether nuclei and organelles of fungal origin have been definitively identified,[19, 20, 21] 2 lines of evidence support the fungal nature of the etiologic agent of lobomycosis. First, immunologic studies show cross-reactivity of the antiserum obtained from patients affected by lobomycosis with several antigens prepared from cultures of P brasiliensis[22, 23] Second, sequence analysis of ribosomal RNA (rRNA) obtained from skin lesions in dolphins are highly homologous to rRNA sequences from the genus Cladosporium[24] and from P brasiliensis.[9]  Emerging data suggest that cetacean lacaziosis-like disease is related to L loboi, but more closely related to P brasiliensis and P lutzii.[2, 25]

L loboi is predominantly an intracellular pathogen. Organisms, singly or in chains, reside predominantly in macrophage vacuoles. They probably reproduce by budding; linear or radiating chains of as many as 20 organisms linked by tubules have been observed.[19] The melanin-containing birefringent 1-μm-thick cell wall[26] resists digestion by macrophages and may be central in contributing to the chronicity of the infection.[19]

The cytokines secreted in vitro by mononuclear cells of patients with lobomycosis showed increased interleukin-4 and interleukin-6 and decreased interleukin-2 production compared with mononuclear cells from normal patients. Mononuclear cells from patients with generalized disease produce higher levels of interferon-gamma than those from patients with localized disease. Taken together, these results suggest that mononuclear cells from patients with lacaziosis are predominantly of the Th2 profile. Further studies are needed to assess the significance of these observations.[27] When compared to healthy control subjects of the same ethnic group no human leukocyte antigen (HLA) susceptibility or resistance could be demonstrated in 21 patients with lobomycosis.[28] However, HLA-DR7 was found to be potentially protective.

The natural reservoir of L loboi is unknown. Its likely habitat is somewhere in the rural environment because of the observed distribution of the disease. Soil and vegetation seem to be likely sources of infection.

L loboi has also been recovered from lobomycotic lesions of the Guiana dolphin Sotalia guianensis from the Surinam River estuary[29, 30] and Tursiops truncatus dolphins in Florida, Hawaii, North Carolina, and the Bay of Biscay in Europe[31, 32, 33, 34, 30, 35] ; these findings imply that some aquatic reservoir also exists. 

Lobomycosis is similarly manifested in humans and in dolphins; the skin lesions and morphologic features of the organism are nearly identical, and at least one case of dolphin-to-human transmission has been documented.[32] However, the organism in dolphins is somewhat smaller than that seen in humans, and it may not prove to be identical.[36] In fact, a recent article suggests that transmission of any kind from dolphins to humans occurs rarely, if at all.[37]

Lobomycosis often develops at sites of minor trauma, but sometimes, no history of trauma can be recalled.[32] The disease has been associated with ear lesions in persons who carry natural materials on their shoulder, with snake and insect bites,[38] and in one case, with trauma associated with exposure to high-pressure falling water.[26] Human-to-human transmission has not been documented, though the inoculation of a tissue homogenate reproduced the disease,[39] and 1 case in Europe may have been caused by occupational exposure to an infected dolphin[32] . Murine-to-human transmission has been postulated but not proven.[40]

Once phagocytized, the organisms initiate a slow replication process, which may account for the slow incubation period and slow development of lesions. Transforming growth factor-β affects mononuclear function, inhibiting expression of interferon-gamma and nitric oxide.[41] In addition, interleukin (IL)–10 has been found to be importantly present in the dermis of affected individuals. Transforming growth factor-β and IL-10 inhibit the cellular immune response, thus altering the function of macrophages.[42]

Mechanisms for dissemination are unclear; however, newer lesions presenting adjacent to affected areas supports dissemination by contiguity or autoinoculation.[41] Although L loboi is generally considered a deep-seated mycosis, it has shown the potential for transepidermal elimination of infectious organisms.[43]

Dissemination within an individual also may occur by means of lymphatic spread.[44] Hematogenous dissemination has been proposed as a possibility, owing to a description of a patient presenting with testicular metastasis.[41]

Epidemiology

Frequency

United States

Only one case of lobomycosis has been reported in the United States. The patient was exposed to a waterfall in Venezuela years before presentation.[26]

International

Approximately 64% of all known cases have occurred in Brazil[27, 45] and though lobomycosis is uncommon, it occurs in as many as 8.5% of the members of some tribes indigenous to South America, for example, the Amoruas tribe of the Casanare state in Colombia and the Caiabi Indians of Brazil.[46, 47] The first report[48] of imported human lobomycosis in Canada was published in 2004 and in South Africa in 2008.[49]

Race

Other than a few tribes in South America (eg, the Amoruas, the Caiabi), no racial prevalence is known. One case has been reported in the United States, but the patient was exposed to a waterfall in Venezuela years before his or her presentation.[26] The case in Europe was reported in a handler of an affected dolphin.[32]

The disease has been reported in many areas: Costa Rica,[38] Panama,[50] Venezuela,[7] Colombia,[47] Guyana,[51] Surinam,[13] French Guyana,[52] Ecuador,[7] Peru,[53] Bolivia,[7] Honduras,[7] Mexico,[54] Holland,[32] the United States,[26] and Canada.[48]

The disease is usually found in areas higher than 200 m with tropical, humid, or subtropical forests; an average temperature of 24°C; and more than 2000 mm of annual rainfall.[44]

Sex

Lobomycosis is more common in men (68-92% of cases) than in women.[55]  The disease is most common in farmers, rubber workers, hunters, and prospectors.[56]  The high prevalence among women of some tribes is attributed to their active participation in farming activities.

Age

The age of onset is 1-70 years, with an average patient age of 38 years.[13]

Prognosis

Lobomycosis does not affect the general health of the patient. Current treatment is disappointing, and most patients continue to have lobomycosis unless it is surgically treated at an early stage. No deaths from lobomycosis have been reported. One patient in whom squamous cell carcinoma developed in a lobomycotic nodule later died from lung metastases.[57]

History

Skin lesions develop slowly.[58] For example, the incubation time in the patient who acquired the disease from an affected dolphin was 3 months,[32] and the incubation period in the American who had traveled to Venezuela was 2.5 years.[26]

When a volunteer was inoculated with the etiologic agent, the lesion was 1 X 2 mm in the first month, and then it waxed and waned. At 5 months, the lesion was a 2- to 3-mm, red papule. At 15 months, it measured 1 cm, with a small telangiectasis. At 25 months, the lesion was 15 X 10 mm, and at 4 years, it measured 33 mm in diameter, and a 4-mm satellite lesion developed.[39]

Because of this slow growth, patients do not present for many years, or they may present only after the lesions become large. The lesions often begin as small papules or pustules, and they may occur at sites of minor trauma.[39]  The lesions may be mildly pruritic, or they may burn.[55]  Single lesions occasionally regress and form scars. However, the disease never disappears, and organisms are identifiable in the scar tissue.[59]  Aside from occasional lymphadenopathy, patients lack other systemic symptoms.[56] However, a recent case report describes a squamous cell carcinoma arising in old lobomycosis lesion scars.[60]

Physical Examination

The disease predominately affects exposed areas and extremities. Examples include the ears, buttocks, lumbosacral area, scapular area, elbows, and lower limbs.[61] The scalp and mucosae are spared.

Lesions, papules, or plaques are most often described as keloidal, but the adjectives gummatous, verrucous, or ulcerative have also been applied.[13]

Lesions have well-defined lobulated margins and are not attached to deeper structures.[62]

The epidermis may be shiny, atrophic, and discolored.[13]

The disease may spread proximally from the extremities and fungal cells have been found in the lymph nodes, indicating lymphatic spread.[47, 63]  Lymph nodes that drain the affected regions may be enlarged and infected with the organism in 0-25% of patients.[13]

See the images below.



View Image

Keloidal nodule on the leg. Courtesy of Dr Roberto Baruzzi, Sao Paulo, Brazil.



View Image

Lobomycosis in this patient appears as a flat plaque lesion. Courtesy of Dr Roberto Baruzzi, Sao Paulo, Brazil.



View Image

Separate keloidal lesions in a localized area. Courtesy of Dr Roberto Baruzzi, Sao Paulo, Brazil.

Causes

Other than geography and possible implantation of organisms through skin trauma,[64] no predisposing factors have been identified.

Important data regarding the interplay among genetic, cultural, and geographic factors have been derived from studies of the Caiabi Indians of Brazil. After they relocated to a geographic area similar to their former one, no new cases have been reported. Furthermore, their original neighbors did not have similar prevalence rates.[65]

Immunodeficiencies appear to occur in patients with lobomycosis. These immunodeficiencies include a delayed skin allograft rejection, a failure to sensitize to dinitrochlorobenzene, and an anergy to Candida species.[66]  Whether the immunodeficiencies are primary and predispose patients to infection or secondary and the result of infection is not known. Based on the large number of fungal cells in the infected tissue and the disorganized cell arrangement in the granuloma, it has been hypothesized that patients with lobomycosis have immunoregulatory disturbances, which are likely to be specific and perhaps responsible for the lack of containment of the pathogen.[67]  One patient infected with the HIV has been reported to have lobomycosis.[68]

Complications

General complications may include the following:

Two cases of squamous cell carcinoma have been reported in long-standing lesions.[57]

Laboratory Studies

Laboratory studies are not required.

Lesions can be gently scraped with a sterile scalpel blade and placed on a microscope slide with a coverslip with or without the use of 10% potassium hydroxide (KOH) or the use of a calcofluor preparation of strips of vinyl adhesive tape may demonstrate the yeast.[43, 48, 69]

An experimental research technique has been developed to determine the viability of L loboi to gauge success of therapy. The method uses fluorescein diacetate-ethidium bromide (FD-EB) vital staining and appears to be reliably sensitive and specific for viability determination of L loboi.[70]

Imaging Studies

Imaging studies are not required.

Other Tests

Other tests are not required.

Miranda and Silva have used vinyl adhesive tape (Scotch test) and direct microscopy to diagnose lobomycosis. This method presumably is possible because of transepidermal elimination of infectious organisms.[43] This test is an attractive, noninvasive, and inexpensive novel technique to diagnose L loboi infection, but additional research is needed to validate the method.

Procedures

Findings on skin biopsy are diagnostic.

Histologic Findings

Histologic examination reveals a granuloma with mostly histiocytes, multinucleated giant cells (average of 10 nuclei), asteroid bodies (ABs), and numerous fungal cells lined up in rows like a child's pop beads.[13, 67, 71] The identified inflammatory cells in a granuloma show the following frequency: CD68+ histiocytes > CD3+ T lymphocytes > CD4+ T lymphocytes > CB8+ T lymphocytes > CD57+ natural-killer cells > CD79+ plasma cells > CD20+ B lymphocytes.[67]

Granulomas are limited in distribution to the dermis,[56] and a delicate layer of collagen may separate the granuloma from the epidermis.[72] The epidermis can be normal, atrophic, or it may have pseudoepitheliomatous hyperplasia,[72] or its papillae may be short.[56]

Xanthomized histiocytes with clear or finely granular eosinophilic cytoplasm occasionally may be seen.[42]

Necrosis is rarely present.[46] Fungal cells are abundant in the macrophages.[19] The fungal cells are highlighted with Gomori Methenamine silver and periodic acid-Schiff stains.[48] Lymphocytes, plasma cells, and leukocytes are found in small numbers.[13] No nerve infiltration is present, and blood and lymphatic vessels are normal.[13]

The presence of intracellular ABs has been described in infiltrating giant cells in granulomatous conditions, including lobomycosis. These ABs have been confused with similar-appearing structures in pathologic specimens obtained from patients with sporotrichosis. Whereas ABs of sporotrichosis consist of a central yeast surrounded by eosinophilic spicules, ABs of lobomycosis are intracellular filamentous structures that contain lipid myelin figures.[73, 74]

See the image below.



View Image

Characteristic histologic appearance of the organism. Courtesy of Dr Roberto Baruzzi, Sao Paulo, Brazil.

 

Medical Care

To date, there have not been any investigations using pharmacological regimens; however, reports have described efficacy for certain regimens in nonsurgical candidates.

A case report described a therapeutic response to 1-year treatment with a combination of clofazimine at 100 mg/d and itraconazole at 100 mg/d.[75] Clofazimine alone improved the lesions in a few patients. Another case report described a patient in Peru who was cured after 27 months of posaconazole with no recurrence after 5 years of follow-up.[76]

Combination itraconazole and clofazimine has been used in the treatment of lobomycosis on the face, with no relapse after 3-year follow up.[77]

Patients with lobomycosis and concurrent leprosy respond to multibacillary therapy, with reduction of pruritus and the size of mycotic nodules.[78]

Surgical Care

The treatment of choice for patients with a localized, surgically amenable form of the disease is surgical excision.[79, 80] Recurrence at the excision site is not uncommon; however, if the disease is detected early, surgical excision may be curative.[72, 79] The major indication for excision is the prevention or correction of disfigurement.

In order to prevent recurrence, itraconazole with cryosurgery has been used successfully to treat relapsing cases.[81]

Diet

No specific dietary changes are required.

Medication Summary

The goals of pharmacotherapy are to reduce morbidity and to prevent complications.

Clofazimine (Lamprene)

Clinical Context:  This agent is no longer commercially available in the United States; it is only available by obtaining an investigational new drug (IND), see Dosing Considerations. Use 100 mg/day PO.

Class Summary

The goals of treatment are to shorten the clinical course, prevent complications, and prevent the development of latency and/or subsequent recurrences, These agents have bactericidal and bacteriostatic activity.

Itraconazole (Onmel, Sporanox, Sporanox Oral Solution)

Clinical Context:  Itraconazole has fungistatic activity. It is a synthetic triazole antifungal agent that slows fungal cell growth by inhibiting CYP450-dependent synthesis of ergosterol, a vital component of fungal cell membranes. Use 100 mg/d PO.

Posaconazole (Noxafil)

Clinical Context:  Posaconazole is a triazole antifungal agent. It blocks ergosterol synthesis by inhibiting the enzyme lanosterol 14-alpha-demethylase and sterol precursor accumulation. This action results in cell membrane disruption. Use 400 mg PO twice daily.

Class Summary

The mechanism of action of antifungal agents may involve an alteration of RNA and DNA metabolism or an intracellular accumulation of peroxide that is toxic to the fungal cell.

Author

Manuel Valdebran, MD, Junior Specialist Physician, Visiting Scholar in Dermatology/Dermatopathology, Department of Dermatology, University of California, Irvine, School of Medicine

Disclosure: Nothing to disclose.

Specialty Editors

David F Butler, MD, Former Section Chief of Dermatology, Central Texas Veterans Healthcare System; Professor of Dermatology, Texas A&M University College of Medicine; Founding Chair, Department of Dermatology, Scott and White Clinic

Disclosure: Nothing to disclose.

Jeffrey P Callen, MD, Professor of Medicine (Dermatology), Chief, Division of Dermatology, University of Louisville School of Medicine

Disclosure: Received honoraria from UpToDate for author/editor; Received royalty from Elsevier for book author/editor; Received dividends from trust accounts, but I do not control these accounts, and have directed our managers to divest pharmaceutical stocks as is fiscally prudent from Stock holdings in various trust accounts include some pharmaceutical companies and device makers for i inherited these trust accounts; for: Allergen; Celgene; Pfizer; 3M; Johnson and Johnson; Merck; Abbott Laboratories; AbbVie; Procter and Gamble; Amgen.

Chief Editor

Dirk M Elston, MD, Professor and Chairman, Department of Dermatology and Dermatologic Surgery, Medical University of South Carolina College of Medicine

Disclosure: Nothing to disclose.

Additional Contributors

Gregory J Raugi, MD, PhD, Professor, Department of Internal Medicine, Division of Dermatology, University of Washington at Seattle School of Medicine; Chief, Dermatology Section, Primary and Specialty Care Service, Veterans Administration Medical Center of Seattle

Disclosure: Nothing to disclose.

Kyle L Horner, MD, MS, Physician, Grace Dermatology and Micrographic Surgery, Lebanon, OR

Disclosure: Nothing to disclose.

Acknowledgements

The authors and editors of Medscape Reference gratefully acknowledge the contributions of previous author, Dr. Kord Honda, MD, to the development and writing of this article.

References

  1. Lobo J. Um caso de blastomicose produzido por uma especie nova encontrada em Recife. Rev Med Pernambucana. 1931. 1:763-75.
  2. Schaefer AM, Reif JS, Guzmán EA, Bossart GD, Ottuso P, Snyder J, et al. Toward the identification, characterization and experimental culture of Lacazia loboi from Atlantic bottlenose dolphin (Tursiops truncatus). Med Mycol. 2016 Aug 1. 54 (6):659-65. [View Abstract]
  3. Fialho A. Blastomicose du tipo "Jorge Lobo". O Hospital. 1938. 14:903.
  4. Borelli D. Aspergillus, sorpresas en micopatologia. Dermatol Venez. 1958. 1:286.
  5. Vilela R, Mendoza L, Rosa PS, Belone AF, Madeira S, Opromolla DV, et al. Molecular model for studying the uncultivated fungal pathogen Lacazia loboi. J Clin Microbiol. 2005 Aug. 43(8):3657-61. [View Abstract]
  6. Ciferri R, Azevedo PC, Campos S. Taxonomy of Jorge Lobo's disease fungus. Inst Micol Univ Recife. 1956. 53:1-21.
  7. Lacaz CS, Baruzzi RG, Rosa MCB. Doenca de Jorge Lobo. San Paulo: Editora da USP-IPSIS Grafica e Editora. 1986.
  8. Taborda PR, Taborda VA, McGinnis MR. Lacazia loboi gen. nov., comb. nov., the etiologic agent of lobomycosis. J Clin Microbiol. 1999 Jun. 37(6):2031-3. [View Abstract]
  9. Herr RA, Tarcha EJ, Taborda PR, Taylor JW, Ajello L, Mendoza L. Phylogenetic analysis of Lacazia loboi places this previously uncharacterized pathogen within the dimorphic Onygenales. J Clin Microbiol. 2001 Jan. 39(1):309-14. [View Abstract]
  10. Mendoza L, Ajello L, Taylor JW. The taxonomic status of Lacazia loboi and Rhinosporidium seeberi has been finally resolved with the use of molecular tools. Rev Iberoam Micol. 2001 Sep. 18(3):95-8. [View Abstract]
  11. Mendoza L, Vilela R, Rosa PS, Fernandes Belone AF. Lacazia loboi and Rhinosporidium seeberi: a genomic perspective. Rev Iberoam Micol. 2005 Dec. 22(4):213-6. [View Abstract]
  12. Sampaio MM, Braga-dias L. The armadillo Euphractus sexcinctus as a suitable animal for experimental studies of Jorge Lobo's disease. Rev Inst Med Trop Sao Paulo. 1977 Jul-Aug. 19(4):215-20. [View Abstract]
  13. Wiersema JP, Niemel PL. Lobo's disease in Surinam patients. Trop Geogr Med. 1965 Jun. 17(2):89-111. [View Abstract]
  14. Opromolla DV, Nogueira ME. Inoculation of Lacazia loboi into the subcutaneous tissue of the hamster cheek pouch. Rev Inst Med Trop Sao Paulo. 2000 May-Jun. 42(3):119-23. [View Abstract]
  15. Sampaio MM, Braga Dias L, Scaff L. Bizarre forms of the aetiologic agent in experimental Jorge Lobo's disease in tortoises. Rev Inst Med Trop Sao Paulo. 1971 May-Jun. 13(3):191-3. [View Abstract]
  16. Madeira S, Opromolla DV, Belone A. Inoculation of BALB/c mice with Lacazia loboi. Rev Inst Med Trop Sao Paulo. 2000 Sep-Oct. 42(5):239-43. [View Abstract]
  17. Belone AF, Madeira S, Rosa PS, Opromolla DV. Experimental reproduction of the Jorge Lobo's disease in BAlb/c mice inoculated with Lacazia loboi obtained from a previously infected mouse. Mycopathologia. 2002. 155(4):191-4. [View Abstract]
  18. Madeira S, Fernandes Belone Ade F, Padovani CR, Araujo Omoprolla DV. Comparative experimental infection of Lacazia loboi in BALB/c and B10.A mice. Rev Iberoam Micol. 2003 Jun. 20(2):55-9. [View Abstract]
  19. Bhawan J, Bain RW, Purtilo DT, et al. Lobomycosis. An electronmicroscopic, histochemical and immunologic study. J Cutan Pathol. 1976. 3(1):5-16. [View Abstract]
  20. Sesso A, Baruzzi RG. Interaction between macrophage and parasite cells in lobomycosis. The thickened cell wall of Paracoccidioides loboi exhibits apertures to the extracellular milieu. J Submicrosc Cytol Pathol. 1988 Jul. 20(3):537-48. [View Abstract]
  21. Woodard JC. Electron microscopic study of lobomycosis (Loboa loboi). Lab Invest. 1972 Dec. 27(6):606-12. [View Abstract]
  22. Landman G, Velludo MA, Lopes JA, Mendes E. Crossed-antigenicity between the etiologic agents of lobomycosis and paraccocidioidomycosis evidenced by an immunoenzymatic method (PAP). Allergol Immunopathol (Madr). 1988 Jul-Aug. 16(4):215-8. [View Abstract]
  23. Camargo ZP, Baruzzi RG, Maeda SM, Floriano MC. Antigenic relationship between Loboa loboi and Paracoccidioides brasiliensis as shown by serological methods. Med Mycol. 1998 Dec. 36(6):413-7. [View Abstract]
  24. Haubold EM, Aronson JF, Cowan DF, McGinnis MR, Cooper CR Jr. Isolation of fungal rDNA from bottlenose dolphin skin infected with Loboa loboi. Med Mycol. 1998 Oct. 36(5):263-7. [View Abstract]
  25. Minakawa T, Ueda K, Tanaka M, Tanaka N, Kuwamura M, Izawa T, et al. Detection of Multiple Budding Yeast Cells and a Partial Sequence of 43-kDa Glycoprotein Coding Gene of Paracoccidioides brasiliensis from a Case of Lacaziosis in a Female Pacific White-Sided Dolphin (Lagenorhynchus obliquidens). Mycopathologia. 2016 Aug. 181 (7-8):523-9. [View Abstract]
  26. Burns RA, Roy JS, Woods C, Padhye AA, Warnock DW. Report of the first human case of lobomycosis in the United States. J Clin Microbiol. 2000 Mar. 38(3):1283-5. [View Abstract]
  27. Vilani-Moreno FR, Lauris JR, Opromolla DV. Cytokine quantification in the supernatant of mononuclear cell cultures and in blood serum from patients with Jorge Lobo's disease. Mycopathologia. 2004 Jul. 158(1):17-24. [View Abstract]
  28. Marcos EV, Souza FC, Torres EA, Lauris JR, Opromolla DV. [Study of the association between human leukocyte antigens and Jorge Lobo's disease]. Rev Soc Bras Med Trop. 2005 Sep-Oct. 38(5):399-401. [View Abstract]
  29. De Vries GA, Laarman JJ. A case of Lobo's disease in the dolphin Sotalia Guianensis. Aquatic Mammels. 1973. 1:26-33.
  30. Paniz-Mondolfi AE, Sander-Hoffmann L. Lobomycosis in inshore and estuarine dolphins. Emerg Infect Dis. 2009 Apr. 15(4):672-3. [View Abstract]
  31. Caldwell DK, Caldwell MC, Woodard JC, Ajello L, Kaplan W, McClure HM. Lobomycosis as a disease of the Atlantic bottle-nosed dolphin (Tursiops truncatus Montagu, 1821). Am J Trop Med Hyg. 1975 Jan. 24(1):105-14. [View Abstract]
  32. Symmers WS. A possible case of Lobo's disease acquired in Europe from a bottle-nosed dolphin (Tursiops truncatus). Bull Soc Pathol Exot Filiales. 1983 Dec. 76(5 Pt 2):777-84. [View Abstract]
  33. Reif JS, Mazzoil MS, McCulloch SD, et al. Lobomycosis in Atlantic bottlenose dolphins from the Indian River Lagoon, Florida. J Am Vet Med Assoc. 2006 Jan 1. 228(1):104-8. [View Abstract]
  34. Norton SA. Dolphin-to-human transmission of lobomycosis?. J Am Acad Dermatol. 2006 Oct. 55(4):723-4. [View Abstract]
  35. Rotstein DS, Burdett LG, McLellan W, et al. Lobomycosis in offshore bottlenose dolphins (Tursiops truncatus), North Carolina. Emerg Infect Dis. 2009 Apr. 15(4):588-90. [View Abstract]
  36. Haubold EM, Cooper CR Jr, Wen JW, McGinnis MR, Cowan DF. Comparative morphology of Lacazia loboi (syn. Loboa loboi) in dolphins and humans. Med Mycol. 2000 Feb. 38(1):9-14. [View Abstract]
  37. Reif JS, Schaefer AM, Bossart GD. Lobomycosis: risk of zoonotic transmission from dolphins to humans. Vector Borne Zoonotic Dis. 2013 Oct. 13(10):689-93. [View Abstract]
  38. Brun AM. Lobomycosis in three Venezuelan patients. Int J Dermatol. 1999 Apr. 38(4):302-5. [View Abstract]
  39. Borelli D. Lobomycosis experimental. Dermatol Venez. 1962. 3:72-82.
  40. Rosa PS, Soares CT, Belone Ade F, et al. Accidental Jorge Lobo''s disease in a worker dealing with Lacazia loboi infected mice: a case report. J Med Case Reports. 2009 Feb 16. 3:67. [View Abstract]
  41. Paniz-Mondolfi A, Talhari C, Sander Hoffmann L, Connor DL, Talhari S, Bermudez-Villapol L, et al. Lobomycosis: an emerging disease in humans and delphinidae. Mycoses. 2012 Jul. 55 (4):298-309. [View Abstract]
  42. Francesconi VA, Klein AP, Santos AP, Ramasawmy R, Francesconi F. Lobomycosis: epidemiology, clinical presentation, and management options. Ther Clin Risk Manag. 2014 Oct 9. 10:851-60. [View Abstract]
  43. Miranda MF, Silva AJ. Vinyl adhesive tape also effective for direct microscopy diagnosis of chromomycosis, lobomycosis, and paracoccidioidomycosis. Diagn Microbiol Infect Dis. 2005 May. 52(1):39-43. [View Abstract]
  44. Azulay RD, Carneiro JA, Da Graca M, Cunha S, Reis LT. Keloidal blastomycosis (Lobo's disease) with lymphatic involvement: a case report. Int J Dermatol. 1976 Jan-Feb. 15(1):40-2. [View Abstract]
  45. Talhari C, Rabelo R, Nogueira L, Santos M, Chrusciak-Talhari A, Talhari S. Lobomycosis. An Bras Dermatol. 2010 Apr. 85(2):239-40. [View Abstract]
  46. Baruzzi RG, Castro RM, D'Andretta C Jr, Carvalhal S, Ramos OL, Pontes PL. Occurrence of Lobo's blastomycosis among "Caiabi," Brazilian Indians. Int J Dermatol. 1973 Mar-Apr. 12(2):95-9. [View Abstract]
  47. Rodríguez-Toro G, Tellez N. Lobomycosis in Colombian Amer Indian patients. Mycopathologia. 1992 Oct. 120(1):5-9. [View Abstract]
  48. Elsayed S, Kuhn SM, Barber D, Church DL, Adams S, Kasper R. Human case of lobomycosis. Emerg Infect Dis. 2004 Apr. 10(4):715-8. [View Abstract]
  49. Al-Daraji WI. Cutaneous lobomycosis: a delayed diagnosis. Am J Dermatopathol. 2008 Dec. 30(6):575-7. [View Abstract]
  50. Tapia A, Torres-Calcindo A, Arosemena R. Keloidal blastomycosis (Lobo's disease) in Panama. Int J Dermatol. 1978 Sep. 17(7):572-4. [View Abstract]
  51. Rose P, Hay RJ. Lobomycosis (Lobo's disease): report of a case from Guyana. Am J Trop Med Hyg. 1981 Jul. 30(4):903-4. [View Abstract]
  52. Pradinaud R. [Between Yucatan, Florida and French Guiana does lobomycosis exist in the Antilles?]. Bull Soc Pathol Exot Filiales. 1984 May-Jun. 77(3):392-400. [View Abstract]
  53. Romero RO. Enfermedad de Jorge Lobo (blastomicosis queloidiana). Primer caso diagnosticado en el Puru. Arch Per Pat Clin. 1972. 26:63-86.
  54. Zavala-Velasquez J, Perez AR. Enfermedad de Lobo (lobomicosis). Primer caso mexicano. Dermatologia (Mex). 1978. 22:5-12.
  55. Baruzzi RG, Lacaz Cda S, de Souza FA. [Natural history of Jorge Lobo's disease. Occurrence among the Caiabi Indians (Central Brazil)]. Rev Inst Med Trop Sao Paulo. 1979 Nov-Dec. 21(6):303-38. [View Abstract]
  56. Fuchs J, Milbradt R, Pecher SA. Lobomycosis (keloidal blastomycosis): case reports and overview. Cutis. 1990 Sep. 46(3):227-34. [View Abstract]
  57. Baruzzi RG, Rodrigues DA, Michalany NS, Salomao R. Squamous-cell carcinoma and lobomycosis (Jorge Lobo''s disease). Int J Dermatol. 1989 Apr. 28(3):183-5. [View Abstract]
  58. Francesconi VA, Klein AP, Santos AP, Ramasawmy R, Francesconi F. Lobomycosis: epidemiology, clinical presentation, and management options. Ther Clin Risk Manag. 2014. 10:851-60. [View Abstract]
  59. Machado P de A. Regrassao espontanea de lesoes maculosas na blastomicose de Jorge Lobo. Acta Amaz (Manaus). 1972. 2:47-50.
  60. Nogueira L, Mendes L, Rodrigues CA, Santos M, Talhari S, Talhari C. Lobomycosis and squamous cell carcinoma. An Bras Dermatol. 2013 Mar-Apr. 88(2):293-5. [View Abstract]
  61. Rodríguez-Toro G. Lobomycosis. Int J Dermatol. 1993 May. 32(5):324-32. [View Abstract]
  62. Lawrence DN, Ajello L. Lobomycosis in western Brazil: report of a clinical trial with ketoconazole. Am J Trop Med Hyg. 1986 Jan. 35(1):162-6. [View Abstract]
  63. Opromolla DV, Belone AF, Taborda PR, Rosa PS. Lymph node involvement in Jorge Lobo's disease: report of two cases. Int J Dermatol. 2003 Dec. 42(12):938-41. [View Abstract]
  64. Pang KR, Wu JJ, Huang DB, Tyring SK. Subcutaneous fungal infections. Dermatol Ther. 2004. 17(6):523-31. [View Abstract]
  65. Baruzzi RG, Marcopito LF, Vicente LS, Michalany NS. Jorge Lobo's disease (keloidal blastomycosis) and tinea imbricata in Indians from the Xingu National Park, Central Brazil. Trop Doct. 1982 Jan. 12(1):13-5. [View Abstract]
  66. Pecher SA, Fuchs J. Cellular immunity in lobomycosis (keloidal blastomycosis). Allergol Immunopathol (Madr). 1988 Nov-Dec. 16(6):413-5. [View Abstract]
  67. Vilani-Moreno FR, Belone AF, Soares CT, Opromolla DV. Immunohistochemical characterization of the cellular infiltrate in Jorge Lobo's disease. Rev Iberoam Micol. 2005 Mar. 22(1):44-9. [View Abstract]
  68. Xavier MB, Ferreira MM, Quaresma JA, de Brito A. HIV and lacaziosis, Brazil. Emerg Infect Dis. 2006 Mar. 12(3):526-7. [View Abstract]
  69. Talhari C, Chrusciak-Talhari A, de Souza JV, Araujo JR, Talhari S. Exfoliative cytology as a rapid diagnostic tool for lobomycosis. Mycoses. 2009 Mar. 52(2):187-9. [View Abstract]
  70. Vilani-Moreno FR, Belone Ade F, Rosa PS, Madeira S, Opromolla DV. Evaluation of the vital staining method for Lacazia loboi through the experimental inoculation of BALB/c mice. Med Mycol. 2003 Jun. 41(3):211-6. [View Abstract]
  71. Quaresma JA, Unger D, Pagliari C, Sotto MN, Duarte MI, de Brito AC. Immunohistochemical study of Langerhans cells in cutaneous lesions of the Jorge Lobo's disease. Acta Trop. 2010 Apr. 114(1):59-62. [View Abstract]
  72. Jaramillo D, Cortes A, Restrepo A, Builes M, Robledo M. Lobomycosis. Report of the eighth Colombian case and review of the literature. J Cutan Pathol. 1976. 3(4):180-9. [View Abstract]
  73. Rodríguez G, Sarmiento L. The asteroid bodies of sporotrichosis. Am J Dermatopathol. 1998 Jun. 20(3):246-9. [View Abstract]
  74. Rodriguez G, Barrera GP. The asteroid body of lobomycosis. Mycopathologia. 1996-1997. 136(2):71-4. [View Abstract]
  75. Fischer M, Chrusciak Talhari A, Reinel D, Talhari S. [Sucessful treatment with clofazimine and itraconazole in a 46 year old patient after 32 years duration of disease]. Hautarzt. 2002 Oct. 53(10):677-81. [View Abstract]
  76. Bustamante B, Seas C, Salomon M, Bravo F. Lobomycosis successfully treated with posaconazole. Am J Trop Med Hyg. 2013 Jun. 88(6):1207-8. [View Abstract]
  77. Fischer M, Chrusciak Talhari A, Reinel D, Talhari S. [Sucessful treatment with clofazimine and itraconazole in a 46 year old patient after 32 years duration of disease]. Hautarzt. 2002 Oct. 53 (10):677-81. [View Abstract]
  78. Woods WJ, Belone Ade F, Carneiro LB, Rosa PS. Ten years experience with Jorge Lobo's disease in the state of Acre, Amazon region, Brazil. Rev Inst Med Trop Sao Paulo. 2010 Sep-Oct. 52 (5):273-8. [View Abstract]
  79. Baruzzi RG, Marcopito LF, Michalany NS, Livianu J, Pinto NR. Early diagnosis and prompt treatment by surgery in Jorge Lobo's disease (keloidal blastomycosis). Mycopathologia. 1981 Apr 10. 74(1):51-4. [View Abstract]
  80. Azevedo Mde C, Rosa PS, Soares CT, Fachin LR, Baptista IM, Woods WJ, et al. Analysis of Immune Response Markers in Jorge Lobo's Disease Lesions Suggests the Occurrence of Mixed T Helper Responses with the Dominance of Regulatory T Cell Activity. PLoS One. 2015. 10 (12):e0145814. [View Abstract]
  81. Carneiro FP, Maia LB, Moraes MA, de Magalhães AV, Vianna LM, Zancanaro PC, et al. Lobomycosis: diagnosis and management of relapsed and multifocal lesions. Diagn Microbiol Infect Dis. 2009 Sep. 65 (1):62-4. [View Abstract]

Keloidal nodule on the leg. Courtesy of Dr Roberto Baruzzi, Sao Paulo, Brazil.

Lobomycosis in this patient appears as a flat plaque lesion. Courtesy of Dr Roberto Baruzzi, Sao Paulo, Brazil.

Separate keloidal lesions in a localized area. Courtesy of Dr Roberto Baruzzi, Sao Paulo, Brazil.

Characteristic histologic appearance of the organism. Courtesy of Dr Roberto Baruzzi, Sao Paulo, Brazil.

Keloidal nodule on the leg. Courtesy of Dr Roberto Baruzzi, Sao Paulo, Brazil.

Lobomycosis in this patient appears as a flat plaque lesion. Courtesy of Dr Roberto Baruzzi, Sao Paulo, Brazil.

Separate keloidal lesions in a localized area. Courtesy of Dr Roberto Baruzzi, Sao Paulo, Brazil.

Characteristic histologic appearance of the organism. Courtesy of Dr Roberto Baruzzi, Sao Paulo, Brazil.